Decitabine upregulated HLA class II molecules in DLBCL cell lines. (A-C) Cells were treated with 125 nM decitabine or 1 μM tazemetostat along with 100 ng/mL IFN-γ for SUDHL-6, SUDHL-10, and WSU-DLCL-2 cell lines and were assayed for expression of HLA-DR/DQ. Mean ± SD is shown for 3 technical replicates per 2 biological replicates. (D-E) Serial dilutions of IFN-γ were performed in the presence or absence of decitabine and tazemetostat for SUDHL-6 and SUDHL-10 cell lines. Mean ± SD is shown for 3 individual replicates. *P < .05; **P < .01; ***P < .001; ****P < .0001.